Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.
genitourinary syndrome
gynecological malignancies
therapy
Journal
Radiology and oncology
ISSN: 1581-3207
Titre abrégé: Radiol Oncol
Pays: Poland
ID NLM: 9317213
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
15
05
2023
accepted:
25
06
2023
medline:
6
9
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
epublish
Résumé
The term genitourinary syndrome of menopause was first used in 2014 by the North American Menopause Society and the International Society for the Study of Women's Sexual Health to describe conditions previously known as atrophic vaginitis, urogenital atrophy, or vulvovaginal atrophy. It is a complex, chronic, progressive condition characterized by a wide range of signs and symptoms affecting sexual function and the tissues of the urinary and genital tracts. The main cause of genitourinary syndrome of menopause is estrogen deficiency caused by ovarian removal or dysfunction. The most bothersome symptoms are vaginal dryness, decreased vaginal lubrication, and pain during penetration and intercourse. They all have a negative impact on the quality of life. The main goal of treatment is to relieve the symptoms. Treatment modalities are pharmacological or non-pharmacological. The first-line treatment for mild to moderate symptoms is the use of personal lubricants and moisturizers, but the gold standard is estrogen replacement therapy. Hormone therapy may not be an option for women with hormone-dependent cancer.
Sections du résumé
BACKGROUND
The term genitourinary syndrome of menopause was first used in 2014 by the North American Menopause Society and the International Society for the Study of Women's Sexual Health to describe conditions previously known as atrophic vaginitis, urogenital atrophy, or vulvovaginal atrophy. It is a complex, chronic, progressive condition characterized by a wide range of signs and symptoms affecting sexual function and the tissues of the urinary and genital tracts. The main cause of genitourinary syndrome of menopause is estrogen deficiency caused by ovarian removal or dysfunction. The most bothersome symptoms are vaginal dryness, decreased vaginal lubrication, and pain during penetration and intercourse. They all have a negative impact on the quality of life.
CONCLUSIONS
The main goal of treatment is to relieve the symptoms. Treatment modalities are pharmacological or non-pharmacological. The first-line treatment for mild to moderate symptoms is the use of personal lubricants and moisturizers, but the gold standard is estrogen replacement therapy. Hormone therapy may not be an option for women with hormone-dependent cancer.
Identifiants
pubmed: 37494601
pii: raon-2023-0038
doi: 10.2478/raon-2023-0038
pmc: PMC10476906
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
292-298Informations de copyright
© 2023 Nina Kovacevic et al., published by Sciendo.
Références
Int J Gynecol Cancer. 2014 Oct;24(8):1527-34
pubmed: 25180463
Am J Obstet Gynecol. 2020 Feb;222(2):103-113
pubmed: 31473229
Am J Obstet Gynecol. 2016 Dec;215(6):704-711
pubmed: 27472999
J Sex Med. 2014 Feb;11(2):487-97
pubmed: 24251418
Support Care Cancer. 2018 Apr;26(4):1335-1343
pubmed: 29164377
Acta Obstet Gynecol Scand. 2022 Jun;101(6):657-692
pubmed: 35484706
Int J Gynecol Cancer. 2021 Mar;31(3):352-359
pubmed: 33127864
Clin Oncol (R Coll Radiol). 2021 Sep;33(9):602-607
pubmed: 34281725
Maturitas. 2005 Jun 16;51(2):172-6
pubmed: 15917158
Gynecol Oncol. 2015 Oct;139(1):141-7
pubmed: 26232519
Menopause. 2020 Sep;27(9):976-992
pubmed: 32852449
Curr Med Res Opin. 2023 Jun;39(6):901-910
pubmed: 37104696
J Clin Endocrinol Metab. 2015 Nov;100(11):3975-4011
pubmed: 26444994
Aust Fam Physician. 2017;46(7):481-484
pubmed: 28697291
J Med Food. 2019 Feb;22(2):127-139
pubmed: 30592686
PLoS One. 2019 Aug 9;14(8):e0221054
pubmed: 31398239
Menopause. 2018 Apr;25(4):430-435
pubmed: 29315133
Gynecol Oncol. 2012 Jun;125(3):661-6
pubmed: 22406638
Climacteric. 2005 Aug;8 Suppl 1:3-63
pubmed: 16112947
Obstet Gynecol. 2016 May;127(5):837-847
pubmed: 27054933
Climacteric. 2016 Apr;19(2):151-61
pubmed: 26707589
Cureus. 2020 Apr 8;12(4):e7586
pubmed: 32399320
J Clin Oncol. 2015 Oct 20;33(30):3394-400
pubmed: 26215946
Gynecol Oncol. 2015 Nov;139(2):355-62
pubmed: 26232517
Menopause. 2018 Jun;25(6):596-608
pubmed: 29762200
Gynecol Oncol. 1987 Feb;26(2):169-77
pubmed: 2433195
BMC Cancer. 2021 Jun 10;21(1):682
pubmed: 34112100
Menopause. 2016 Mar;23(3):243-56
pubmed: 26731686
Maturitas. 2021 Jan;143:47-58
pubmed: 33308636
Menopause. 2013 Apr;20(4):418-27
pubmed: 23096251
J Sex Med. 2015 Jan;12(1):198-209
pubmed: 25402322
J Clin Oncol. 2006 Feb 1;24(4):587-92
pubmed: 16446331
Eur J Cancer. 2014 Jun;50(9):1628-37
pubmed: 24685478
Int J Gynecol Cancer. 2020 Apr;30(4):515-524
pubmed: 32075898
PLoS One. 2020 Mar 20;15(3):e0230625
pubmed: 32196536
Prz Menopauzalny. 2019 Jun;18(2):116-122
pubmed: 31488961
Menopause. 2002 May-Jun;9(3):179-87
pubmed: 11973441
Menopause. 2013 Sep;20(9):973-9
pubmed: 23481118
Cancers (Basel). 2020 Jun 21;12(6):
pubmed: 32575821
Medicine (Baltimore). 2022 Jan 28;101(4):e28705
pubmed: 35089231
Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):400-413
pubmed: 34478833
BMC Womens Health. 2022 Jul 22;22(1):305
pubmed: 35869476
Curr Opin Support Palliat Care. 2016 Mar;10(1):44-54
pubmed: 26716390
Maturitas. 2014 Mar;77(3):274-81
pubmed: 24411556
Climacteric. 2018 Apr;21(2):167-173
pubmed: 29411644
Gynecol Oncol. 2020 May;157(2):303-306
pubmed: 32067815
Cancer. 2014 Mar 1;120(5):738-43
pubmed: 24222211
Menopause. 2014 Oct;21(10):1063-8
pubmed: 25160739
Clin Exp Obstet Gynecol. 2001;28(4):274-6
pubmed: 11838758
Medicina (Kaunas). 2022 Sep 05;58(9):
pubmed: 36143900